{
  "success": true,
  "fetched_at": "2026-02-01T03:24:32.291123",
  "ticker": "3407",
  "ticker_full": "3407.T",
  "company_name": "ASAHI KASEI CORP",
  "company_info": {
    "name_en": "ASAHI KASEI CORP",
    "long_name": "Asahi Kasei Corporation",
    "sector": "Industrials",
    "industry": "Conglomerates",
    "website": "https://www.asahi-kasei.com",
    "employees": 50352,
    "country": "Japan",
    "city": "Tokyo",
    "address": "Hibiya Mitsui Tower",
    "description": "Asahi Kasei Corporation engages in material, homes, healthcare businesses. The company offers Pimel photosensitive polyimide/PBO precursor, a liquid photosensitive material for buffer coating and packaging applications; Sunfort dry film photoresist to form circuit patterns on printed wiring boards; Novacure, a latent curing agent for epoxy resin with storage stability; glass fabric for printed circuit boards; plastic optical fiber; suede products under the Dinamica name; Microza UF and MF industrial membranes and systems; Aciplex membranes, process equipment, and systems for caustic soda production; Hipore, a microporous polyolefin sheet which prevents the anode and cathode from contacting one another; Celgard, a lithium-ion battery separator; Deramic, a lead acid battery separator; photopolymers and platemaking systems; and fiber products under the Bemberg, ROICA, ELTAS, Bemliese, EUTEC, Precisé, SEMIA, smash, PULSHUT, Lastan, Cubit, NanoAct, ECORISE, BioCradle, CMC-Bemliese names. It also provides cling film, bags and containers, and dishwashing liquid under the Saran Wrap, Ziploc, Cookper, Frosch names; packaging products under the OPS, Suntec, Barrialon, PVDC latex, and Saran names; pharmaceutical and food additives under the Ceolous and Celphere names; and clads and anchors under the Baclad and AR Chemical Setter names. In addition, the company is involved in the provision of remodeling services; real estate-related operations; offers unit homes and apartment buildings; autoclaved aerated concrete, foundation systems, thermal insulation material, structural systems and components products; prescription drugs in the fields of orthopedics, critical/intensive care, urology, immune system, and central nervous system; enzymes and diagnostic products; and hemodialysis, therapeutic apheresis, and autologous blood-related businesses. The company was founded in 1931 and is headquartered in Tokyo, Japan."
  },
  "price_trend": {
    "ma_5": {
      "ma_value": 1486.2,
      "deviation": 0.89,
      "trend": "up"
    },
    "ma_25": {
      "ma_value": 1458.6,
      "deviation": 2.8,
      "trend": "up"
    },
    "ma_75": {
      "ma_value": 1336.63,
      "deviation": 12.18,
      "trend": "up"
    },
    "ma_200": {
      "ma_value": 1155.28,
      "deviation": 29.8,
      "trend": "up"
    }
  },
  "financials": {
    "years": [
      {
        "year": 2025,
        "revenue": 3037312000000.0,
        "revenue_fmt": "¥3.0T",
        "gross_profit": 958260000000.0,
        "gross_profit_fmt": "¥9583億",
        "operating_income": 211920000000.0,
        "operating_income_fmt": "¥2119億",
        "ebit": 203698000000.0,
        "ebit_fmt": "¥2037億",
        "net_income": 134997000000.0,
        "net_income_fmt": "¥1350億",
        "eps": 99.4,
        "operating_margin": 6.98,
        "total_assets": 4015214000000.0,
        "total_assets_fmt": "¥4.0T",
        "total_equity": 1859421000000.0,
        "total_equity_fmt": "¥1.9T",
        "total_debt": 1195045000000.0,
        "total_debt_fmt": "¥1.2T",
        "total_cash": 393467000000.0,
        "total_cash_fmt": "¥3935億",
        "equity_ratio": 46.31,
        "de_ratio": 0.64,
        "current_ratio": 1.83,
        "operating_cf": 301489000000.0,
        "operating_cf_fmt": "¥3015億",
        "investing_cf": -381150000000.0,
        "investing_cf_fmt": "-¥3812億",
        "financing_cf": 144567000000.0,
        "financing_cf_fmt": "¥1446億",
        "free_cf": 83550000000.0,
        "free_cf_fmt": "¥836億",
        "net_margin": 4.44,
        "roe": 7.26,
        "roa": 3.36
      },
      {
        "year": 2024,
        "revenue": 2784878000000.0,
        "revenue_fmt": "¥2.8T",
        "gross_profit": 815969000000.0,
        "gross_profit_fmt": "¥8160億",
        "operating_income": 140746000000.0,
        "operating_income_fmt": "¥1407億",
        "ebit": 36291000000.0,
        "ebit_fmt": "¥363億",
        "net_income": 43806000000.0,
        "net_income_fmt": "¥438億",
        "eps": 31.6,
        "operating_margin": 5.05,
        "total_assets": 3662730000000.0,
        "total_assets_fmt": "¥3.7T",
        "total_equity": 1813391000000.0,
        "total_equity_fmt": "¥1.8T",
        "total_debt": 955561000000.0,
        "total_debt_fmt": "¥9556億",
        "total_cash": 338108000000.0,
        "total_cash_fmt": "¥3381億",
        "equity_ratio": 49.51,
        "de_ratio": 0.53,
        "current_ratio": 1.8,
        "operating_cf": 295300000000.0,
        "operating_cf_fmt": "¥2953億",
        "investing_cf": -142598000000.0,
        "investing_cf_fmt": "-¥1426億",
        "financing_cf": -94331000000.0,
        "financing_cf_fmt": "-¥943億",
        "free_cf": 123346000000.0,
        "free_cf_fmt": "¥1233億",
        "net_margin": 1.57,
        "roe": 2.42,
        "roa": 1.2
      },
      {
        "year": 2023,
        "revenue": 2726485000000.0,
        "revenue_fmt": "¥2.7T",
        "gross_profit": 773776000000.0,
        "gross_profit_fmt": "¥7738億",
        "operating_income": 127716000000.0,
        "operating_income_fmt": "¥1277億",
        "ebit": -56634000000.0,
        "ebit_fmt": "-¥566億",
        "net_income": -91947000000.0,
        "net_income_fmt": "-¥919億",
        "eps": -66.3,
        "operating_margin": 4.68,
        "total_assets": 3453900000000.0,
        "total_assets_fmt": "¥3.5T",
        "total_equity": 1660296000000.0,
        "total_equity_fmt": "¥1.7T",
        "total_debt": 974748000000.0,
        "total_debt_fmt": "¥9747億",
        "total_cash": 251181000000.0,
        "total_cash_fmt": "¥2512億",
        "equity_ratio": 48.07,
        "de_ratio": 0.59,
        "current_ratio": 1.63,
        "operating_cf": 90804000000.0,
        "operating_cf_fmt": "¥908億",
        "investing_cf": -213584000000.0,
        "investing_cf_fmt": "-¥2136億",
        "financing_cf": 111780000000.0,
        "financing_cf_fmt": "¥1118億",
        "free_cf": -81354000000.0,
        "free_cf_fmt": "-¥814億",
        "net_margin": -3.37,
        "roe": -5.54,
        "roa": -2.66
      },
      {
        "year": 2022,
        "revenue": 2461317000000.0,
        "revenue_fmt": "¥2.5T",
        "gross_profit": 769769000000.0,
        "gross_profit_fmt": "¥7698億",
        "operating_income": 202647000000.0,
        "operating_income_fmt": "¥2026億",
        "ebit": 218764000000.0,
        "ebit_fmt": "¥2188億",
        "net_income": 161880000000.0,
        "net_income_fmt": "¥1619億",
        "eps": 116.68,
        "operating_margin": 8.23,
        "total_assets": 3349075000000.0,
        "total_assets_fmt": "¥3.3T",
        "total_equity": 1687411000000.0,
        "total_equity_fmt": "¥1.7T",
        "total_debt": 777215000000.0,
        "total_debt_fmt": "¥7772億",
        "total_cash": 244641000000.0,
        "total_cash_fmt": "¥2446億",
        "equity_ratio": 50.38,
        "de_ratio": 0.46,
        "current_ratio": 1.44,
        "operating_cf": 183271000000.0,
        "operating_cf_fmt": "¥1833億",
        "investing_cf": -221019000000.0,
        "investing_cf_fmt": "-¥2210億",
        "financing_cf": 42321000000.0,
        "financing_cf_fmt": "¥423億",
        "free_cf": 13563000000.0,
        "free_cf_fmt": "¥136億",
        "net_margin": 6.58,
        "roe": 9.59,
        "roa": 4.83
      }
    ],
    "has_data": true
  },
  "dividends": {
    "history": [
      {
        "year": 2021,
        "amount": 34.0
      },
      {
        "year": 2022,
        "amount": 35.0
      },
      {
        "year": 2023,
        "amount": 36.0
      },
      {
        "year": 2024,
        "amount": 36.0
      },
      {
        "year": 2025,
        "amount": 40.0
      }
    ],
    "latest": 20.0,
    "has_data": true
  }
}